Prior Authorization Expiring Before a Refill: Preparing the Reauthorization Record

When a prior authorization expires before the next refill, the pharmacy claim may reject because the approval no longer applies. Confirm the approval period and the exact rejection message before treating the problem as a renewal. Medi-Cal Rx documents reject 75 when certain drugs lack an approved authorization; New York Medicaid documents reject EV when a submitted authorization has expired, is unapproved, or has exhausted its units. Other claim conditions and program-specific supply options can affect what happens next. Prepare the reauthorization record before the end date using four dated inputs: the approval notice, the current drug-specific policy, any history and continuation evidence that policy requires, and the applicable review clock. The record lets the team identify missing evidence and a filing deadline; it does not guarantee coverage.

What Actually Expires: Reading the Approval Notice as a Source Document

The approval notice is the first document in the reauthorization record. For Medicare Part D, the rule is explicit: when a plan sponsor approves a standard coverage determination, the notice "must explain the conditions of the approval in a readable and understandable form" (42 CFR 423.568(e)), and the same requirement applies to a completely favorable expedited decision (42 CFR 423.572(c)(1)). Commercial and Medicaid approvals follow their own rules; the fields below are the ones that control renewal timing wherever they appear.

Not every notice prints all of the fields below. Where a condition is unclear, ask the plan or pharmacy benefit manager (PBM) to confirm it in writing before the end date. These fields help distinguish a lapsed approval from a product, quantity or benefit-routing mismatch:

• Authorization reference. The identifier the plan uses for the approval. Cite it in the renewal request and in any call so the reviewer can match the request to the existing case.

• Approval period. The start and end dates. Refills remaining on the prescription do not extend it. New York Medicaid's edit reference describes what happens when a pharmacy submits a prior authorization number after the end date: the number is not accepted because the authorization "has expired, is not approved, or all approved units have been exhausted" (NYRx Top Edit Resource).

• Approved product. Drug, strength and dosage form, sometimes the NDC. A dose or formulation change during maintenance therapy can fall outside the approval before the end date. Check whether the approval names a strength or the drug as a whole.

• Quantity and days' supply. Units per fill or per period, and sometimes a total unit count. A total can run out before the calendar end date, which produces the same reject as expiry.

• Dispensing conditions. Any specialty pharmacy, mail-order or site-of-care requirement attached to the approval or the plan's benefit design.

• Renewal conditions. Anything the notice says a renewal must show, such as documented response. If the notice is silent, the plan's current criteria document governs, as described below.

Express Scripts explains in its member FAQ that an expired approval or plan change can prompt a new coverage review using current information. It describes uninterrupted plan coverage when renewal is approved before expiration, and full member cost for continued fills without approval. This is one PBM's description, subject to the member's plan; submitting a request before expiration is not the same as obtaining approval.

How Expiry Shows Up First: Reject Codes at the Pharmacy Counter

A rejected refill can bring an unnoticed end date to the team's attention. Reject codes come from the NCPDP pharmacy claim standard, but the reason behind a code and the message attached to it are set by each program. Two program documents dated in 2026 show the range: the NYRx Top Edit Resource (version February 26, 2026) and the Medi-Cal Rx notice of March 6, 2026. The table maps what each program says a reject means and whether it points to an expired approval.

Track the approval end date and the next eligible refill date as separate fields. In an illustrative case, the approval ends October 15 and the pharmacy response gives October 10 as the next eligible date. That date precedes expiry, but the claim still has to satisfy the other coverage conditions. A response giving October 20 instead places the next claim after expiry. Neither date can be inferred reliably from the last fill alone: NYRx evaluates 90 days of history, and its guide says the returned date can vary with edit sequencing. A fill before expiry also does not extend the authorization. Use the actual pharmacy response for eligibility and the dispensing record for supply; do not calculate a later refill date simply by adding 30 days to an early fill.

Program Conditions: Decision Clocks That Set the Filing Lead Time

Set the filing deadline by working backward from the authorization end date and the next refill at risk. Allow time to assemble evidence, receive the applicable decision and, if needed, request review of a denial. Record the estimated supply-exhaustion date separately: it shows how much runway remains rather than adding days to the review clock. The table below concerns pharmacy-benefit drug requests. For Part D, identify whether the request seeks ordinary PA approval or an exception, because the clock-starting event differs. Medicaid and commercial rules require separate program identification.

The missed-deadline rule protects against silence; it does not approve anything. Under 42 CFR 423.568(h), 423.572(d) and 423.590(c) and (e), a Part D plan that misses its deadline has made an adverse decision by default and must forward the case to the IRE within 24 hours. The case moves to an outside reviewer; the drug is not approved. A redetermination that upholds a denial is different. It is not forwarded automatically, and the denial notice must instead tell the enrollee about the right to request reconsideration. For exception requests, 423.568(b) and 423.572(a) also provide a fallback if no supporting statement arrives within 14 calendar days: notification is due within the applicable 72 or 24 hours after that period ends. Do not treat a missing statement as an indefinitely paused request.

Do not borrow the non-drug clock. The CMS-0057-F final-rule fact sheet sets 72-hour expedited and seven-calendar-day standard timeframes for specified payers, excluding QHP issuers on the federal exchanges. Its drug prior authorization exclusion means those timeframes cannot establish a pharmacy-benefit reauthorization deadline. Use the Part D drug-benefit rules, the applicable Medicaid covered-outpatient-drug process, or the commercial plan's documents and governing requirements.

The 2025 AMA prior authorization physician survey provides context for the stakes, not a renewal-specific risk estimate. In a December 2025 web survey of 1,000 practicing physicians, 95% reported care delays at least sometimes, 79% reported that PA issues can at least sometimes lead to treatment abandonment, and 35% said criteria are rarely or never evidence-based. These are physician self-reports about PA broadly; they do not measure how often an expired approval causes a treatment gap.

Plan and Product Conditions: The Current Criteria Document Governs the Renewal

Renewal criteria are drug-specific and revisable. In Part D, the plan's pharmacy and therapeutics committee "reviews and approves all clinical prior authorization criteria, step therapy protocols, and quantity limit restrictions applied to each covered Part D drug" (42 CFR 423.120(b)(1)). The practical consequence is that the evidence list for a renewal comes from the plan's current policy for that drug, not from the original approval letter or a generic checklist.

The South Country Health Alliance criteria book effective May 1, 2026 separates 3-month initial and 12-month renewal terms for ACL inhibitors when criteria are met.

• Separate renewal evidence. Nexletol and Nexlizet initially require baseline LDL-C and statin history. Renewal requires clinical benefit, with LDL-C reduction as an example. Preserve both measurements.

• A distinct continuation override. This pathway requires other-payer coverage and 90 days at consistent dosage; cash pay, manufacturer debit cards, samples and free goods do not qualify.

• Read the pathway-specific duration. The general override is limited to 90 days, with no repeat for the same drug. Existing-PA and mental-health provisions differ from ordinary renewal.

Program rules can also change in the middle of an approval cycle. Medi-Cal Rx generally approves prior authorizations for up to 12 months under California regulations, with longer terms considered case by case, and some authorizations received extended-duration approvals under its Transition Policy. Its March 6, 2026 notice announced updates effective that date. The paid-claims lookback dropped from 450 days to 100 days, and "if prior claims history is greater than 100 days, a new PA request may be required." The extended-duration policy ended for a listed set of drugs, so claims without an approved authorization now deny with 75. Authorizations approved under the Transition Policy no longer bypass utilization-management limits. These changes followed a separate set of program updates on January 1, 2026. A record that would have passed in December could fail in March without any change in the patient's condition.

The Reauthorization Record: A Worked Example

This is an illustrative worksheet, not a payer form or real patient dataset. Bracketed fields are placeholders. Assume an approval ending October 15, 2026 and a request received September 25. The timing calculation uses an ordinary Part D drug-benefit determination, not an exception or payment request. The separate 100-day history illustration uses the Medi-Cal Rx window to show date arithmetic; it is not presented as a Part D requirement or as a combined payer policy. Replace each assumption with the member's actual program, approval and criteria.

Keep three operational dates visible: the approval end date, the pharmacy's returned next eligible fill date, and the filing date. Do not assume a pre-expiry fill guarantees the next one. For the Part D timing illustration, an ordinary request received September 25 must receive a standard decision within 72 hours, by the same time on September 28, or sooner if health requires. If it is denied and a standard drug-benefit redetermination is received September 29, the seven-calendar-day maximum reaches October 6. Both decisions could therefore occur before the assumed October 15 expiry. The example allows no guarantee of approval and does not include a further IRE review, delays before an appeal is filed, or an exception's supporting-statement trigger.

These are regulatory maximums for the specified Part D paths, not predictions of actual turnaround. Record receipt time as well as date. A completed worksheet may still need additional policy-specific evidence, and the plan may deny the request. Use current criteria to decide what belongs in the packet rather than treating the eight rows as a universally sufficient submission.

Conditions That Look Like Expiry but Are Not

Not every reject during maintenance therapy means an approval has lapsed, and not every approval lapses the same way. Before building a renewal, check whether one of these mechanisms applies instead:

• Approved Part D exceptions. Once a tiering or non-formulary exception is approved, the plan "may not require the enrollee to request approval for a refill, or a new prescription to continue using the Part D prescription drug after the refills for the initial prescription are exhausted." That holds as long as the prescriber continues to prescribe, the drug remains safe for the condition, and the enrollment period has not expired. The plan may choose to continue coverage into the next plan year (42 CFR 423.578(c)(3)-(4)). These exception provisions do not establish the duration of an ordinary PA approval. Check the mechanism named in the letter and any separate continuation policy.

• Negative formulary changes. Adding a prior authorization, step therapy or quantity limit requirement, or making one more restrictive, is a negative formulary change. Apart from immediate substitutions and market withdrawals, a Part D sponsor must give affected enrollees written notice at least 30 days before the change takes effect, or provide an approved month's supply under the previous terms with written notice at the refill. Non-maintenance changes need CMS approval, and affected enrollees are exempt from them for the rest of the contract year (42 CFR 423.120(e)-(f)). A new PA-related reject on a drug that previously needed no authorization may reflect a policy change; read the notice and verify the claim conditions first. Our guide to formulary change notices and existing authorizations covers that decision.

• Transition supplies. The Part D transition process covers new enrollees after the annual election period, newly eligible Medicare enrollees, people who switch plans after the contract year starts, and current enrollees affected by formulary changes. It provides a one-time temporary supply of at least an approved month's supply within the first 90 days of coverage under a new plan (42 CFR 423.120(b)(3)). Expiry of an individual same-plan approval alone does not establish eligibility under those transition provisions. Check whether an enrollment or formulary-change event also applies. Medi-Cal Rx's Transition Policy is a separate, program-specific policy, and since March 6, 2026 approvals granted under it no longer bypass utilization-management limits.

• A plan change. A new plan year or a new insurer can require a new authorization even when the old one has time left on it. Our article on whether a prior authorization transfers to a new insurance plan covers that case.

If the Gap Opens Anyway: The Same-Week Sequence

Gaps still happen: a visit slips, a lab is late, or the end date was never logged. When a refill has already rejected and supply is short, the order of operations matters. The sequence below follows the Part D rules; Medicaid and commercial programs use their own timelines.

flowchart TD
    A["Pharmacy refill claim rejects"] --> B{"Read reject and full message"}
    B -->|"PA absent, expired or exhausted"| C["Verify notice, units and claim history"]
    B -->|"Fill too soon"| D["Check returned date and program exceptions"]
    B -->|"Quantity, dose or clinical criterion"| E["Reconcile claim with prescription and policy"]
    C --> F["Prepare request under current criteria"]
    E --> F
    F --> G{"Part D review path"}
    G -->|"Standard drug-benefit determination"| I["72-hour maximum from request receipt"]
    G -->|"Expedited handling accepted"| H["24-hour maximum from request receipt"]
    G -->|"Exception request"| O["Supporting-statement trigger; see 14-day fallback below"]
    I --> J{"Decision"}
    H --> J
    O --> J
    J -->|"Approved"| K["Pharmacy reprocesses; other edits may remain"]
    J -->|"Denied"| L["Request redetermination if pursuing appeal"]
    J -->|"Deadline missed"| M["Plan forwards to IRE within 24 hours"]
    L --> P["7 calendar days standard; 72 hours expedited"]
    P -->|"Favorable"| K
    P -->|"Adverse"| N["Right to request IRE reconsideration"]
    P -->|"Deadline missed"| M

1. Read the exact reject and message. A 79 identifies early-fill timing; a 75 or EV calls for authorization and claim-history checks. EV can also follow an overly rapid reversal and resubmission. A quantity or dose message may require claim correction, clinical documentation or authorization. Reconcile billing with the actual prescription and current policy; any treatment change belongs with the prescriber.

2. Assemble the policy-specific packet. Use the worksheet to identify the approval being renewed and the evidence required today. Sending all required material together makes omissions easier to spot; it does not guarantee a first-pass decision. For an expedited Part D redetermination, the plan must request needed medical information within 24 hours of the initial request and still meet its 72-hour deadline (42 CFR 423.590(d)).

3. Confirm the review path and clock trigger. If expedited handling is accepted, 42 CFR 423.572(a) sets a maximum of 24 hours after receipt of the request, not 24 hours after a later grant of expedited handling. For an exception request, it runs from receipt of the prescriber's supporting statement. Document the applicable trigger and discuss urgency with the prescriber and plan.

4. Log receipt and watch the deadline. Record when the plan received the request. If no decision arrives within the applicable timeframe, the regulation treats it as an adverse decision and requires the plan to forward the case to the IRE within 24 hours. Confirm that the forwarding happened rather than resubmitting.

5. Be honest about the supply gap. Options depend on the program. In New York Medicaid, a pharmacist who cannot reach the prescriber and whose patient's medication requires immediate attention may contact the program's PA line to authorize up to a 72-hour emergency supply of a drug that requires prior authorization, and drugs bought for cash instead of waiting for the authorization are not reimbursable to the member (NYRx). Express Scripts tells members they are responsible for the full cost if they keep filling without approval. Any manufacturer bridge supply is separate from the plan's decision; see our comparison of Part D transition fills and manufacturer bridge programs.

What Changes in 2026–2027: End Dates Become Data

An approval letter or portal record can show an end date without automatically creating a reliable renewal reminder. CMS's electronic prior authorization policies address structured exchange of authorization information. Separate the requirements already finalized for non-drug PA from the proposed extension to drugs.

Under CMS-0057-F, impacted payers (Medicare Advantage organizations, Medicaid and CHIP fee-for-service programs and managed care plans, and QHP issuers on the federally facilitated exchanges) must run Prior Authorization APIs that communicate an approval "and the date or circumstance under which the authorization ends," with API compliance dates generally beginning January 1, 2027. Operational provisions began January 1, 2026, and the initial set of prior authorization metrics was due by March 31, 2026. These prior authorization requirements exclude drug PA; that does not mean the rule excludes all drug-related claims data from every API.

CMS released the 2026 Interoperability Standards and Prior Authorization for Drugs proposed rule (CMS-0062-P) on April 10, 2026. CMS's electronic prior authorization overview, last modified September 14, 2026, still lists it as a proposed rule. If it is finalized as proposed, it would:

• Extend electronic prior authorization to drugs. Medical-benefit drugs would move through the Prior Authorization APIs. Medicaid and CHIP programs and plans and QHP issuers on the federal exchanges would support the NCPDP SCRIPT, Formulary and Benefit, and Real-Time Prescription Benefit standards for pharmacy-benefit drugs, in line with existing Medicare Part D requirements. The proposed start date is October 1, 2027.

• Expose the end date. Drug prior authorization details would flow through the Patient Access, Provider Access and Payer-to-Payer APIs, including status, approval date, "the date or circumstance under which the authorization ends," and the drug and dosage approved. The proposed compliance date is October 1, 2027.

• Align decision clocks by drug and program. The proposal distinguishes Medicaid and managed CHIP covered outpatient drugs (24 hours) from other drugs subject to the seven-day standard and 72-hour expedited framework. CHIP fee-for-service prescription drugs would use a 24-hour limit; federal-exchange QHP drug requests would use 72 hours standard and 24 hours expedited. The proposed compliance dates begin October 1, 2027.

If finalized as proposed, the drug PA data-sharing provisions would make authorization end conditions available through the specified APIs. That is not evidence that every provider system would automatically schedule renewals. Teams still need to reconcile the returned information with the current approval and drug policy. Every CMS-0062-P date above is proposed and may change before finalization; use the current plan workflow while monitoring the proposal.

Questions the Record Cannot Answer

The record organizes a reviewable request and exposes missing inputs. It cannot answer every access question:

• Turnaround outside the cited rules. Commercial and state-program timeframes depend on the program and applicable requirements. Use the plan's own documents and applicable state law to set lead time; the Part D clocks are not a proxy.

• Whether a renewal is actually pending. New York Medicaid has accepted electronic prior authorization requests through CoverMyMeds since July 15, 2025, and other plans and platforms run their own electronic workflows. Where someone else is said to have started the renewal, confirm in writing that a request is pending. At the counter, a renewal that was never submitted looks the same as one that was denied.

• Disputes over the criteria themselves. A complete record can still fail a criterion the prescriber disputes. Over a third of physicians in the AMA survey said prior authorization criteria are rarely or never evidence-based. Once a renewal is denied, the work becomes an appeal; our guide to renewal denials after stable disease covers that path.

• When to escalate. If a renewal is denied, read the stated reason and compare it with the current criteria and submitted evidence. Identify whether a correction, missing document or appeal is appropriate. Part D provides a redetermination path; other programs have their own review procedures.

Sources

• 42 CFR 423.120 - Access to covered Part D drugs. eCFR, Office of the Federal Register. P&T committee review of prior authorization criteria, the transition process, and negative formulary change approval and notice.

• 42 CFR 423.568 - Standard timeframe and notice requirements for coverage determinations. eCFR. The 72-hour standard clock, approval-notice content, and the missed-deadline rule.

• 42 CFR 423.572 - Timeframes and notice requirements for expedited coverage determinations. eCFR. The 24-hour expedited clock and favorable-notice content.

• 42 CFR 423.578 - Exceptions process. eCFR. Refill continuation for approved tiering and non-formulary exceptions.

• 42 CFR 423.590 - Timeframes and responsibility for making redeterminations. eCFR. The 7-day standard and 72-hour expedited redetermination clocks and IRE forwarding.

• CMS Interoperability and Prior Authorization Final Rule (CMS-0057-F) fact sheet. Centers for Medicare & Medicaid Services, January 17, 2024. Impacted payers, decision timeframes, compliance dates, and the exclusion of drug PA.

• 2026 CMS Interoperability Standards and Prior Authorization for Drugs Proposed Rule (CMS-0062-P) fact sheet. Centers for Medicare & Medicaid Services, April 10, 2026. Proposed drug ePA standards, end-date disclosure, and decision timeframes.

• Electronic Prior Authorization overview. Centers for Medicare & Medicaid Services, page last modified September 14, 2026. Current status of CMS-0062-P as a proposed rule.

• Now Active: Prior Authorization Policy Updates. Medi-Cal Rx, California Department of Health Care Services, March 6, 2026. The lookback change from 450 to 100 days, the end of Transition Policy bypass, extended-duration changes and reject codes.

• Prior Authorization Criteria, effective 5/1/2026. South Country Health Alliance (Minnesota Medical Assistance). Coverage-duration fields, initial and reauthorization criteria, and continuation-of-therapy rules.

• NYRx, The Medicaid Pharmacy Program: Top Edit Resource. New York State Medicaid pharmacy program, version February 26, 2026. Reject 75 sub-reasons, the EV expired-PA edit, the early-fill rule and the emergency supply process.

• My prescription was approved before. Why do I need a new coverage review (prior authorization)?. Express Scripts member FAQ. Coverage continuity when renewal is approved before expiration, and member cost if it is not.

• 2025 AMA Prior Authorization Physician Survey. American Medical Association. Physician-reported care delays, treatment abandonment, and views on whether criteria are evidence-based.